Welcome to VIRTTU

VIRTTU Biologics is a clinical stage biotechnology company pioneering the development of oncolytic immunotherapies to treat cancer.

By remodelling a common Herpes Simplex virus (HSV) we have developed and patented a series of novel agents that target many forms of cancer effectively and have the potential to transform treatment.

SEPREHVIR®, our most advanced programme, is a unique cancer-destroying oncolytic immunotherapy that has the potential to radically change cancer therapy through its ability to:

(i) seek out and multiply only in cancer cells, destroying them while leaving healthy cells unaffected and;

(ii) stimulate a long lasting anti-tumour immune response.

We are now actively advancing the clinical development programme required to secure regulatory approval to market our lead programme, SEPREHVIR®, for use in cancer therapy.

In parallel, VIRTTU has an exciting development pipeline of next-generation oncolytic immunotherapies which build on the SEPREHVIR® concept by engineering additional therapeutic genes into the SEPREHVIR® backbone.